These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 17976974

  • 1. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
    Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB.
    Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 3. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
    Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB.
    Clin Cancer Res; 2008 Jul 01; 14(13):4225-31. PubMed ID: 18594004
    [Abstract] [Full Text] [Related]

  • 4. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, Danenberg PV, Harpole DH.
    Clin Cancer Res; 2005 Mar 15; 11(6):2215-21. PubMed ID: 15788669
    [Abstract] [Full Text] [Related]

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 15; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 6. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV.
    J Am Coll Surg; 2005 Mar 15; 200(3):336-44. PubMed ID: 15737843
    [Abstract] [Full Text] [Related]

  • 7. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
    Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, Hofler H.
    J Surg Oncol; 2010 Oct 01; 102(5):503-8. PubMed ID: 20589706
    [Abstract] [Full Text] [Related]

  • 8. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, Nonomura N.
    Clin Cancer Res; 2011 Apr 15; 17(8):2561-9. PubMed ID: 21177407
    [Abstract] [Full Text] [Related]

  • 11. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
    Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH.
    Br J Cancer; 2010 Sep 07; 103(6):845-51. PubMed ID: 20700125
    [Abstract] [Full Text] [Related]

  • 12. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM.
    Clin Cancer Res; 2004 Jun 01; 10(11):3794-9. PubMed ID: 15173087
    [Abstract] [Full Text] [Related]

  • 13. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
    Harpole DH, Moore MB, Herndon JE, Aloia T, D'Amico TA, Sporn T, Parr A, Linoila I, Allegra C.
    Clin Cancer Res; 2001 Mar 01; 7(3):562-9. PubMed ID: 11297249
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
    Okumura H, Natsugoe S, Matsumoto M, Yokomakura N, Uchikado Y, Takatori H, Ishigami S, Takao S, Aikou T.
    J Surg Oncol; 2005 Jul 01; 91(1):84-9. PubMed ID: 15999354
    [Abstract] [Full Text] [Related]

  • 15. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 16. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.
    Ariga H, Nemoto K, Miyazaki S, Yoshioka T, Ogawa Y, Sakayauchi T, Jingu K, Miyata G, Onodera K, Ichikawa H, Kamei T, Kato S, Ishioka C, Satomi S, Yamada S.
    Int J Radiat Oncol Biol Phys; 2009 Oct 01; 75(2):348-56. PubMed ID: 19735862
    [Abstract] [Full Text] [Related]

  • 17. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
    Sobajima J, Haga N, Kumamoto K, Ishibashi K, Ishida H.
    Gan To Kagaku Ryoho; 2010 Nov 01; 37(12):2394-6. PubMed ID: 21224584
    [Abstract] [Full Text] [Related]

  • 18. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.
    Int J Oncol; 2008 Dec 01; 33(6):1257-62. PubMed ID: 19020759
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
    Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ.
    Biomarkers; 2011 Feb 01; 16(1):74-82. PubMed ID: 21133646
    [Abstract] [Full Text] [Related]

  • 20. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
    Miyoshi N, Yano M, Takachi K, Kishi K, Noura S, Eguchi H, Yamada T, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Doki Y, Imaoka S.
    J Surg Oncol; 2009 Apr 01; 99(5):302-6. PubMed ID: 19170110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.